Aug 27 2012
BioTime, Inc. (NYSE MKT: BTX) announced that the company has amended its
license from the University of Utah to expand the field of use for which
BioTime is licensed to produce and market products covered by the core
patents underlying HyStem® technology.
Under the amended license, BioTime now is licensed worldwide for all
uses, with the exception of veterinary medicine and animal health. The
field of use includes, but is not limited to, all human pharmaceutical
and medical device applications, all tissue engineering and regenerative
medicine uses, and all research applications. Previously, BioTime's
license in the United States was not exclusive and the fields of use of
the technology permitted by the license were not as broad.
"We are pleased to have an exclusive license to the full spectrum of
human medical products possible with HyStem®,"
said William Tew, Ph.D., Chief Commercial Officer at BioTime. "In
addition to Renevia™ which is currently in preclinical studies,
we have initiated development programs for additional products that are
planned as relatively near-term sources of revenue while strategically
laying the foundation for the wide array of cell-based regenerative
therapies that may be developed based on stem cell sciences."
Source: BioTime, Inc.
Utilizing process Raman in optimizing cultivated meat production